New telitacicept deal aims to advance MG therapy outside China
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
